Fibronectin pattern in benign hyperplasia and cancer of the prostate

Disease Markers

Volumn 25, Issue 1, 2008, Pages 49-58

  Janković, Miroslava M ^a   Kosanović, Maja M ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Biological activity; Cancer marker; Glycosylation; Molecular forms

Indexed keywords

CONCANAVALIN A; FIBRONECTIN; LECTIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BIOCHEMISTRY; CELL ADHESION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FIBROBLAST; GLYCOSYLATION; HUMAN; IMMUNOBLOTTING; IMMUNOREACTIVITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN STRUCTURE;

EID: 50249178094     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/308420     Document Type: Article

References (58)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu and M.J. Thun, Cancer statistics, 2007, CA Cancer J Clin 57(1) (2007), 43-66.
2. R.J. Black, F. Bray, J. Ferlay and D.M. Parkin, Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990, Eur J Cancer 33 (1997), 1075-1107.
3. C.J. Girman, Population-based studies of the epidemiology of benign prostatic hyperplasia, Br J Urol 82 (Supl 1) (1998), 34-43.
4. G.W. Chodak, R.A. Thisted, G.S. Gerber, J.E. Johansson, J. Adolfsson, G.W. Jones, G.D. Chisholm, B. Moskovitz, P.M. Livne and J. Warner, Results of conservative management of clinically localized prostate cancer, N Engl J Med 330(4) (1994), 242-248.
5. M.J. Barry, F.J. Jr. Fowler, L. Bin, J.C. 3rd Pitts, C.J. Harris and A.G. Jr. Mulley, The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists, J Urol 157(1) (1997), 10-14.
6. G.W. Cannon and R.H. Getzenberg, Biomarkers for benign prostatic hyperplasia progression, Current Prostate Reports 5(3) (2007), 121-125.
7. J.V Tricoli, M. Schoenfeldt and B.A, Detection of prostate cancer and predicting progression: current and future diagnostic markers, Clin Cancer Res 10(12Pt1) (2004), 3943-3953.
8. H.G. van der Poel, Molecular markers in the diagnosis of prostate cancer, Crit Rev Oncol Hematol 61(2) (2007), 104-139.
9. M.M. Janković and M.M. Kosanović, Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns, Clin Biochem 38(1) (2005), 58-65.
10. S. Golubovic and M. Jankovic, Glycobiochemical characterization of salivary carcinoembryonic antigen, J BUON 12(2) (2007), 269-275.
11. D.F. Mosher, Fibronectin, Prog Hemost Thromb 5 (1980), 111-151.
12. R.O. Hynes and K.M. Yamada, Fibronectins: multifunctional modular glycoproteins, J Cell Biol 95(2 Pt 1) (1982), 369-377.
13. C. Ffrench-Constant, Alternative splicing of fibronectin-many different proteins but few different functions, Exp Cell Res 221(2) (1995), 261-271.
14. R. Pankov and K.M. Yamada, Fibronectin at a glance, J Cell Sci 115(Pt 20) (2002), 3861-3863.
15. U. Koçak, U. Ezer and S. Vidinlisan, Serum fibronectin in neonatal sepsis: is it valuable in early diagnosis and outcome prediction? Acta Paediatr Jpn 39(4) (1997), 428-432.
16. M.E. Lancer and G.E. Brown, Induction of hepatocytes synthesis of fibronectin by a non-interleukin 1 monokine, Journal of Trauma 28(8) (1988), 1220-1225.
17. F. Boccardo, D. Guarneri, S. Zanardi, P. Castellani, L. Borsi and L. Zardi, Fibronectin concentration in the plasma of patients with malignant and benign breast disease, Cancer Lett 33(3) (1986), 317-323.
18. S. Jung, G. Jung, A. Tranzer and R. Dörr, Blood fibronectin changes in various neoplasms, Presse Med 15(5) (1986), 197-198, 203-204.
19. C. Haglund, S. Ylätupa, P. Mertaniemi and P. Partanen, Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA, Br J Cancer 76(6) (1997), 777-783.
20. J. Labat-Robert, Fibronectin in malignancy, Semin Cancer Biol 12(3) (2002), 187-195.
21. F. Grinnell and M. Zhu, Identification of neutrophil elastase as the proteinase in burn wound fluid responsible for degradation of fibronectin, J Invest Dermatol 103(2) (1994), 155-161.
22. M.L. Barilla and S.E. Carsons, Fibronectin fragments and their role in inflammatory arthritis, Semin Arthritis Rheum 29(4) (2000), 252-265.
23. J.M. Guo, X.Y. Zhang, H.L. Chen, G.M. Wang and Y.K. Zhang, Structural alterations of sugar chains in urine fibronectin from bladder cancer patients and its enzymatic mechanism, J Cancer Res Clin Oncol 127(8) (2001), 512-519.
24. A. Hegele, A. Heidenreich, J. Kropf, R. von Knobloch, Z. Varga, R. Hofmann and P. Olbert, Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma, Tumor Biol 25(3) (2004), 111-116.
25. U.M. Warawdekar, S.M. Zingde, K.S. Iyer, P. Jagannath, A.R. Mehta and N.G. Mehta, Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients, Clin Chim Acta 372(1-2) (2006), 83-93.
26. H. Sönmez, S. Süer, I. Karaarslan, H. Baloǧlu and E.Kökoǧlu, Tissue fibronectin levels of human prostatic cancer, as a tumor marker, Cancer Biochem Biophys 15(2) (1995), 107-110.
27. M. Albrecht, H. Renneberg, G. Wennemuth, O. Möschler, M. Janssen, G. Aumüller and L. Konrad, Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance, Histochem Cell Biol 112(1) (1999), 51-61.
28. S. Chakrabarty and H.A. Fritsche, Fibronectin and prostate cancer, Journal of Clinical Ligand Assay 25 (2002), 74-79.
29. M. Morgan, S. Saba and W. Gower, Fibronectin influences cellular proliferation and apoptosis similarly in LNCaP and PC-3 prostate cancer cell lines, Urol Oncol 5(4) (2000), 155-159.
30. D.L. Livant, R.K. Brabec, K.J. Pienta, D.L. Allen, K. Kurachi, S. Markwart and A. Upadhyaya, Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma, Cancer Res 60(2) (2000), 309-320.
31. E. Ruoslahti, E.G. Hayman, M. Pierschbacher and E. Engvall, Fibronectin: purification, immunochemical properties, and biological activities, Methods Enzymol 82 (Pt A) (1982), 803-831.
32. U. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227(1970), 680-685.
33. 131I labelled growth hormone of high specific radioactivity, Biochem J 89 (1963), 114-120.
34. Y. Gluzman, SV40-transformed simian cells support the replication of early SV40 mutants, Cell 23(1) (1981), 175-182.
35. http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum= CRL-1651.
36. M. Hyytiäinen and J. Keski-Oja, Latent TGF-beta binding protein LTBP-2 decreases fibroblast adhesion to fibronectin, J Cell Biol 163(6) (2003), 1363-1374.
37. I. Katnik-Prastowska, M. Przybysz, A. Chełmońska-Soyta, Fibronectin fragments in human seminal plasma, Acta Biochim Pol 52(2) (2005), 557-560.
38. M.M. Webber, A. Waghray and D. Bello, Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion, Clin Cancer Res 1(10) (1995), 1089-1094.
39. http://www.copewithcytokines.de/cope.cgi?key=Fibronectin.
40. Y. Yamaguchi, M. Isemura, M. Kosakai, A. Sato, M. Suzuki, M. Kan and Z. Yosizawa, Characterization of fibronectin from fetal human plasma in comparison with adult plasma fibronectin, Biochim Biophys Acta 790(1) (1984), 53-60.
41. T. Krusius, M. Fukuda, A. Dell and E. Ruoslahti, Structure of the carbohydrate units of human amniotic fluid fibronectin, J Biol Chem 260(7) (1985), 4110-4116.
42. S. Carsons, B.B. Lavietes, A. Slomiany, H.S. Diamond and E. Berkowitz, Carbohydrate heterogeneity of fibronectins. Synovial fluid fibronectin resembles the form secreted by cultured synoviocytes but differs from the plasma form, J Clin Invest 80(5) (1987), 1342-1349.
43. E. Köttgen, B. Hell, C. Müller, F. Kainer and R. Tauber, Developmental changes in the glycosylation and binding properties of human fibronectins. Characterization of the glycan structures and ligand binding of human fibronectins from adult plasma, cord blood and amniotic fluid, Biol Chem Hoppe Seyler 370(12) (1989), 1285-1294.
44. M. Takamoto, T. Endo, M. Isemura, N. Kochibe and A. Kobata, Structures of asparagine-linked oligosaccharides of human placental fibronectin, J Biochem (Tokyo) 105(5) (1989), 742-750.
45. M. Takamoto, T. Endo, M. Isemura, Y. Yamaguchi, K. Okamura, N. Kochibe and A. Kobata, Detection of bisected biantennary form in the asparagine-linked oligosaccharides of fibronectin isolated from human term amniotic fluid, J Biochem (Tokyo) 106(2) (1989), 228-235.
46. M . Tajiri, S. Yoshida and Y. Wada, Differential analysis of site-specific glycans on plasma and cellular fibronectins: application of a hydrophilic affinity method for glycopeptide enrichment, Glycobiology 15(12) (2005), 1332-1340.
47. K. Murayama, E.J. Nichols, S.B. Levery, W.G. Carter and S. Hakomori, The carbohydrate structure of human fibronectins: Acomparison between normal embryonic lung fibroblasts WI38 and the SV40 virus transformed cell line VA13, Glycoconjugate Journal 1(2) (1984).
48. H. Matsuura and S. Hakomori, The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma, Proc Natl Acad Sci USA 82(19) (1985), 6517-6521.
49. E.J. Nichols, B.A. Fenderson, W.G. Carter and S. Hakomori, Domain-specific distribution of carbohydrates in human fibronectins and the transformation-dependent translocation of branched type 2 chain defined by monoclonal antibody C6, J Biol Chem 261(24) (1986), 11295-11301.
50. H. Matsuura, T. Greene and S. Hakomori, An alpha-N- acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin, J Biol Chem 264(18) (1989), 10472-10476.
51. U. Mandel, Hamilton, M. Therkildsen, J. Reibel, B. Sweeney, H. Matsuura, S. Hakomori, E. Dabelsteen and H. Clausen, Cancer-associated changes in glycosylation of fibronectin. Immunohistological localization of oncofetal fibronectin defined by monoclonal antibodies, APMIS 100(9) (1992), 817-826.
52. http://home.comcast.net/∼kennethingham/newsite/intro.
53. G.E. Jones, R.G. Arumugham and M.L Tanzer, Fibronectin glycosylation modulates fibroblast adhesion and spreading, J Cell Biol 103(5) (1986), 1663-1670.
54. A.J. Millis, M. Hoyle, D.M. Mann and M.J. Brennan, Incorporation of cellular and plasma fibronectins into smooth muscle cell extracellular matrix in vitro, Proc Natl Acad Sci USA 82(9) (1985), 2746-2750.
55. F.A. Moretti, A.K. Chauhan, A. Iaconcig, F. Porro, F.E. Baralle and A.F. Muro, A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived, J Biol Chem 282(38) (2007), 28057-28062.
56. M. Yi and E. Ruoslahti, A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis, Proc Natl Acad Sci USA 98(2) (2001), 620-624.
57. M. Fornaro, J. Plescia, S. Chheang, G. Tallini, Y.M. Zhu, M, King, D.C. Altieri and L.R. Languino, Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway, J Biol Chem 278(50) (2003), 50402-50411.
58. K.L. van Golen, L. Bao, G.J. Brewer, K.J. Pienta, J.M. Kamradt, D.L. Livant and S.D. Merajver, Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma, Neoplasia 4(5) (2002), 373-379.